Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial

Open access

Abstract

Choroideremia is a rare, X-linked retinal degeneration resulting in progressive vision loss. A randomized, masked, phase 3 clinical trial evaluated the safety and efficacy over 12 months of follow-up in adult males with choroideremia randomized to receive a high-dose (1.0 × 10 11 vector genomes (vg); n = 69) or low-dose (1.0 × 10 10 vg; n = 34) subretinal injection of the AAV2-vector-based gene therapy timrepigene emparvovec versus non-treated control ( n = 66). Most treatment-emergent adverse events were mild or moderate. The trial did not meet its primary endpoint of best-corrected visual acuity (BCVA) improvement. In the primary endpoint analysis, three of 65 participants (5%) in the high-dose group, one of 34 (3%) participants in the low-dose group and zero of 62 (0%) participants in the control group had ≥15-letter Early Treatment Diabetic Retinopathy Study (ETDRS) improvement from baseline BCVA at 12 months (high dose, P = 0.245 versus control; low dose, P = 0.354 versus control). As the primary endpoint was not met, key secondary endpoints were not tested for significance. In a key secondary endpoint, nine of 65 (14%), six of 35 (18%) and one of 62 (2%) participants in the high-dose, low-dose and control groups, respectively, experienced ≥10-letter ETDRS improvement from baseline BCVA at 12 months. Potential opportunities to enhance future gene therapy studies for choroideremia include optimization of entry criteria (more preserved retinal area), surgical techniques and clinical endpoints. EudraCT registration: 2015-003958-41 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02520-3

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Retinal images and microperimetry plot from a patient with advanced choroideremia. a, AF imaging reveals the fluorescent shapes that represent the surviving retinal pigment epithelium centrally (green arrows). b, The microperimetry plot shows that the central triangular area of AF is broadly correlated with the surviving visual field (red dots). c, The green box shows the region of optical coherence tomography scan, with the scan along the green arrow shown in d. d, The surviving outer nuclear layer is the area above the green arrows, with disruption of the outer segments indicating early degeneration.
Fig. 1 Retinal images and microperimetry plot from a patient with advanced choroideremia. a, AF imaging reveals the fluorescent shapes that represent the surviving retinal pigment epithelium centrally (green arrows). b, The microperimetry plot shows that the central triangular area of AF is broadly correlated with the surviving visual field (red dots). c, The green box shows the region of optical coherence tomography scan, with the scan along the green arrow shown in d. d, The surviving outer nuclear layer is the area above the green arrows, with disruption of the outer segments indicating early degeneration.CC BY · PubMed Central
Fig. 2 Participant disposition. Flow chart showing pattern of participant recruitment, randomization and follow-up.
Fig. 2 Participant disposition. Flow chart showing pattern of participant recruitment, randomization and follow-up.CC BY · PubMed Central
Fig. 3 Visual acuity changes in trial participants. a–d, In all cases, the eyes treated with gene therapy had numerically better outcomes than unoperated control eyes, both in terms of the proportion gaining lines of vision and in the mean changes in visual acuity. Proportion of participants with ≥15-letter ETDRS improvement from baseline (a), LS mean change from baseline (b), proportion of participants with ≥10-letter ETDRS improvement from baseline (c) and proportion of participants with no or <5-letter ETDRS decrease from baseline (d) in BCVA (ETDRS letters) in the study eye at month 12 for the intent-to-treat population. LS mean change from baseline was calculated using the ANCOVA model, which includes factors for surgical group and study arms and baseline value of the assessment as covariate. Missing data were imputed by the last observation carried forward approach. Error bars represent 95% CI.
Fig. 3 Visual acuity changes in trial participants. a–d, In all cases, the eyes treated with gene therapy had numerically better outcomes than unoperated control eyes, both in terms of the proportion gaining lines of vision and in the mean changes in visual acuity. Proportion of participants with ≥15-letter ETDRS improvement from baseline (a), LS mean change from baseline (b), proportion of participants with ≥10-letter ETDRS improvement from baseline (c) and proportion of participants with no or <5-letter ETDRS decrease from baseline (d) in BCVA (ETDRS letters) in the study eye at month 12 for the intent-to-treat population. LS mean change from baseline was calculated using the ANCOVA model, which includes factors for surgical group and study arms and baseline value of the assessment as covariate. Missing data were imputed by the last observation carried forward approach. Error bars represent 95% CI.CC BY · PubMed Central
Extended Data Fig. 1 Study design for the STAR phase 3 trial. IOP, intraocular pressure; SLE, slit lamp examination.
Extended Data Fig. 1 Study design for the STAR phase 3 trial. IOP, intraocular pressure; SLE, slit lamp examination.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 1

  1. European Medicines Agency. EU Regulatory Workshop – Ophthalmology – Summary and Report. https://www.ema.europa.eu/en/documents/report/european-union-regulatory-workshop-ophthalmology-summary-report_en.pdf (2012).

Cited by

See all 58

Metadata

Authors
MacLaren, R. E., Fischer, M. D., Gow, J. A., Lam, B. L., Sankila, E.-M. K., Girach, A., Panda, S., Yoon, D., Zhao, G., & Pennesi, M. E.
Affiliations
  • University of Oxford (GB)
  • University of Tübingen (DE)
  • Biogen (United States) (US)
  • University of Miami (US)
  • University of Helsinki (FI)
  • Oregon Health & Science University (US)
Corresponding author
MacLaren, Robert E.
Venue
Nature Medicine
Published
2023-10
Volume
29
Issue
10
Pages
2464-2472
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4387451521
Cited by
58
References
35
Citations by year
2026: 15 · 2025: 22 · 2024: 17 · 2023: 4
FWCI
5.15
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • Työväentutkimus Vuosikirja (submittedVersion)
Funders
This study was funded by Biogen.
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
choroideremia, subretinal gene therapy, X-linked retinal degeneration, best-corrected visual acuity, treatment-emergent adverse events, dose comparison, adult male patient
MeSH terms
Adult, Diabetic Retinopathy, Humans, Male, Retina, Visual Acuity, Genetic Therapy, Choroideremia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial. https://app.cochat.ai/papers/10.1038/s41591-023-02520-3
The paper
MacLaren, R. E., Fischer, M. D., Gow, J. A., Lam, B. L., Sankila, E.-M. K., Girach, A., Panda, S., Yoon, D., Zhao, G., & Pennesi, M. E. (2023). Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02520-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.